Respiratory syncytial virus (RSV) is usually filed away as a childhood illness, but it is also a leading cause of hospitalization among older adults, and the vaccine recommendations built around that risk have changed more than once in a short span of time. For readers trying to understand whether they, or an older relative, actually qualify for an RSV vaccine, the honest answer is: it depends on age and health status, and the rules are more layered than a single yes-or-no.
From "ask your doctor" to a tiered recommendation
When RSV vaccines for adults were first authorized, U.S. guidance from the Advisory Committee on Immunization Practices (ACIP), the body that sets recommendations later adopted by the CDC, took a cautious approach. Adults 60 and older could receive a single dose, but only after "shared clinical decision-making" — a conversation with a clinician weighing individual risk factors rather than a blanket recommendation. That framing changed as more real-world data accumulated on who actually benefits most.
The guidance was subsequently narrowed into three tiers that better reflect where severe RSV disease actually concentrates: a universal recommendation for the oldest adults, a risk-based recommendation for a middle band of ages, and a further expansion for younger adults who carry specific risk factors. That structure is the part most people miss when they hear "RSV vaccine for adults" treated as a single, uniform product decision.
The three age tiers, in plain terms
| Age group | Recommendation type | What it means in practice |
|---|---|---|
| 75 and older | Universal | A single dose is recommended for essentially everyone in this age band, regardless of underlying health conditions. |
| 60–74 | Risk-based | Recommended specifically for those with elevated risk — chronic heart or lung conditions, a weakened immune system, certain other underlying conditions, or residence in a nursing home or long-term care setting. |
| 50–59 (added later) | Risk-based, expanded | The same higher-risk criteria as the 60–74 group, extended downward once evidence supported it. |
Two details are easy to overlook. First, this is currently a one-time dose, not an annual shot like influenza vaccination — someone who has already received an RSV vaccine is not expected to get another dose on a recurring schedule under current guidance. Second, there is no preferential recommendation among the different FDA-licensed RSV vaccine products available for this age range; the choice between them is a conversation for a clinician’s office, not a public-health-level distinction.
Why the shift away from "ask your doctor"
Shared clinical decision-making is a reasonable starting point when a vaccine is new and the population-level risk data is still thin — it puts judgment in the hands of a patient and their clinician rather than a rigid rule. But it also creates friction: it depends on the conversation actually happening, on a clinician remembering to raise it, and on a patient walking in already primed to ask. As follow-up data clarified which age and health profiles carry the highest burden of severe RSV illness, the guidance moved toward the more actionable tiered structure above, precisely because it removes ambiguity for the group at the highest, most consistent risk.
This is also where the "vaccine-preventable disease" framing matters most: RSV in older adults, particularly those with chronic cardiopulmonary disease, can escalate quickly to hospitalization. A recommendation structure that names concrete age and risk criteria is easier for both patients and primary care practices to act on consistently than one that relies on an open-ended discussion every visit.
How this differs from RSV protection for infants
It is worth being precise about a common point of confusion: the RSV vaccine recommended for older adults is a different intervention, given for a different reason, than RSV protection for infants. Protecting newborns relies on either vaccinating a pregnant person during a defined window in the third trimester — so antibodies pass to the baby before birth — or giving an infant a monoclonal antibody product directly. Older-adult vaccination works by prompting the person’s own immune system to respond; infant protection is passive, borrowed immunity that fades after their first RSV season. They share a virus and a vaccine-preventable-disease category, but the clinical logic behind each recommendation is distinct, and conflating the two is a common source of confusion in casual conversation about "the RSV shot."
What this means for readers
The practical takeaway is narrower than the headlines suggest: age 75 or older is now a straightforward "yes" conversation with a primary care provider; ages 50 to 74 hinge on whether specific chronic conditions or living situations apply. Anyone unsure where they fall should bring the question directly to a clinician rather than assuming either automatic eligibility or automatic exclusion — the risk-based criteria are specific enough that a short conversation, not a guess, is what settles it. As with any vaccine-preventable disease covered here, the guidance itself will likely continue to be refined as more seasons of real-world data accumulate; this is where the current tiered structure stands as of the most recent update.